Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins

Journal of Medicinal Chemistry

Volumn 39, Issue 11, 1996, Pages 2170-2177

  Gazit, Aviv ^a   App, Harald ^b   McMahon, Gerald ^b   Chen, Jefferey ^b   Levitzki, Alexander ^a   Bohmer, Frank D ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b SUGEN INC   (United States)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 NITROPHENYL) 3 CARBOMETHOXY 6,7 DIMETHOXYQUINOLINE; 2 CARBOXY 3 PHENYL 6,7 DIMETHYLQUINOXALINE; 3 PHENYL 1,4 DIAZAANTHRACENE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ENZYME INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; DRUG CONFORMATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; GROWTH INHIBITION; MOUSE; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ANIMALS; CELL MEMBRANE; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; INDICATORS AND REAGENTS; INDOLES; MICE; MOLECULAR STRUCTURE; NITRILES; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; QUINOLINES; QUINOXALINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029899585     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950727b     Document Type: Article

References (32)

1. Claesson-Welsh, L. Platelet-derived growth factor receptor signals. J. Biol. Chem. 1994, 269, 32023-32026.
2. Leveen, P.; Pekny, M.; Gebre-Medhin, S.; Swolin, B.; Larsson, E.; Betsholtz, C. Mice deficient for PDGF B show renal, cardiovascular and hematological abnormalities. Genes Dev. 1994, 8, 1875-1887.
3. Soriano, P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 1994, 8, 1888-1896.
4. Ross, R.; Raines, E. W.; Bowen-Pope, D. F. The biology of platelet-derived growth factor. Cell 1986, 46, 155-169.
5. Heldin, C. H.; Westermark, B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1990, 1, 555-566.
6. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362, 801-809.
7. Heldin, C. H.; Westermark, B. Platelet derived growth factor and autocrine mechanisms of oncogenic processes. Crit. Rev. Oncog. 1991, 2, 109-124.
8. Vassbotn, F. S.; Andersson, M.; Westermark, B.; Heldin, C. H.; Ostman, A. Reversion of autocrine transformation by a dominant negative platelet derived growth factor mutant. Mol. Cell Biol. 1993, 13, 4066-4076.
9. Shamah, S. M.; Stiles, C. D.; Guha, A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol. Cell Biol. 1993, 13, 7203-7212.
10. Figarella-Branger, D.; Vagner-Cappodano, A. M.; Bouillot, P.; Graziani, N.; Gambarelli, D.; Devictor, B.; Zattara-Cannoni, H.; Bianco, N. Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis. Neuropathol. Appl. Neurobiol. 1994, 20, 439-447.
11. Seymour, L.; Dajee, D.; Bezwoda, W. R. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res. Treat. 1993, 26, 247-252.
12. Henriksen, R.; Funa, K.; Wilander, E.; Backstrom, T.; Ridderheim, M.; Oberg, K. Expression and prognostic significance of platelet-derived growth factor and its receptros in epithelial ovarian neoplasms. Cancer Res. 1993, 53, 4550-4554.
13. Henriksen, R.; Funa, K.; Wilander, E.; Bakcstrom, T.; Ridderheim, M.; Oberg, K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993, 53, 4550-4554.
14. Chaudhry, A.; Papanicolaou, V.; Oberg, K.; Heldin, C. H.; Funa, K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res. 1992, 52, 1006-1012.
15. Black, P. M.; Carroll, R.; Glowacka, D.; Riley, K.; Dashner, K. Platelet-derived growth factor expression and stimulation in human meningiomas. J. Neurosurg. 1994, 81, 388-393.
16. Bilder, G. E.; Kasiewski, C. J.; Walczac, E. M.; Perrone, M. H. PDGF-receptor protein tyrosine kinase activity in carotid artery is enhanced by injury and inhibited in Vivo by Tyrphostin RG 13291. Drug Dev. Res. 1993, 29, 158-66.
17. Bryckaert, M. C.; Eldor, A.; Gazit, A.; Osherov, N.; Gilon, C.; Fontenay, M.; Levitzki, A.; Tobelem, G. Inhibition of Platelet derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. Exp. Cell. Res. 1992, 199, 255-261.
18. Maguire, M. P.; Sheets, K. R.; McVety, K.; Spada, A. P.; Zilberstein, A. A new series of PDGF receptor kinase inhibitors; 3-substituted quinoline derivatives. J. Med. Chem. 1994, 37, 2129-2137.
19. Dalle, R. E.; et al. 5,7-Dimethoxy, 3(4-pyridinyl) quinoline is a potent and selective Inhibitor of Human Vascular β-type Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 1994, 37, 2627-2629.
20. Kovalenko, M.; Gazit, A.; Bohmer, C. R.; Rorsman, C.; Ronnstrand, L.; Heldin, C. H.; Waltenberger, J.; Bohmer, F. D. Selective PDGF receptor kinase blockers reverse sis-transformation. Cancer Res. 1994, 54, 6106-6114.
21. Spada, A. P.; Maguire, M. P.; Persons, P. E.; Myers, M. R. Bis Mono and Bicyclic Aryl and Heteroaryl compounds which Inhibit EGF and/or PDGF receptor tyrosine kinase. International Patent Application WO 92/20642, Nov. 26, 1992 (priority date: May 10, 1991); Ann. drug data report 1993, 588.
22. Buchdunnger, E.; Zimmerman, J.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2558-2562.
23. Meth-Cohn, O.; Rhouati, S.; Tarnowski, B.; Robinson, A. Versatile new synthesis of quinolines. Conversion of anilides into 3-substituted quinolines. J. Chem. Soc., Perkin Trans. I 1981, 1537-1544.
24. Rapoport, Z.; Gazit, A. Complete and partial stereoconversion in vinylic substitution of E and Z-β-chloro phenyl cinnamaldehyde. J. Org.Chem. 1985, 50, 3184-3192.
25. The bisthiosemicarbazones were available in this laboratory from previous work and prepared from thiosemicarbazone and the ketoaldehydes (A. Gazit, unpublished results).
26. Burke, T. R., Jr.; Ford, H.; Osherov, N.; Levitzki, A.; Stefanova, I.; Horak, I.; Marquez, V. Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors. Bioorg. Med. Chem. 1992, 12, 1771-1774.
27. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P.; Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins II: Heterocyclic and α-substituted Benzenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine kinases. J. Med. Chem. 1991, 34, 1896-1907.
28. Van Order, R. B.; Lindwall, H. G. 3-Indole aldehyde and certain of its condensation products. J. Org. Chem. 1945, 10, 128-132.
29. Carboni, R. A.; Coffman, P. D.; Howard, E. G. Cyano carbon chemistry. Malononitrile dimer. J. Am. Chem. Soc. 1958, 80, 2838-2840.
30. Thom, D.; Powell, A. J.; Lloyd, C. W.; Rees, D. A. Rapid isolation of plasma membranes in high yield from cultured fibroblasts. Biochem. J. 1977, 168, 187-194.
31. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
32. Baudy, R. B.; et al. Potent quinaxoline spaced phosphono α-aminoacids of the AP-6 type as competitive NMDA antagonist: synthesis and biological evaluation. J. Med. Chem. 1993, 36, 331-342.